Aim: Aim of this study was to assess the efficiency of different treatment modalities for oral submucous fibrosis.Materials and methods: Sixty patients were included in the study, which was diagnosed as stage II oral submucous fibrosis (OSMF) based on habitual history and clinical findings. Three groups were made after randomization, i.e., group 1: capsule lycopene group, group 2: capsule lycopene and injection dexamethasone, group 3: injection dexamethasone and hyaluronidase group. Symptom severity was done by visual analog scale (VAS) scoring system viz burning sensation/pain in the patients; patient satisfaction was assessed. Vernier calipers were used to measure patients' maximum mouth opening at day 1, 1st month, 2nd month, 3rd month.

No abstract

Background: Urinary tract infections (UTIs) are the most frequent bacterial infections, commonly seen in females. High degree of antimicrobial resistance in uropathogens has challenged the use of therapeutic agents. Fosfomycin which is an old antibiotic with distinctive characteristics, seems to be a promising novel therapeutic agent with a good bactericidal activity towards multi-drug resistant (MDR) uropathogens. Objective: The main objective of the study is to evaluate the antibacterial activity of fosfomycin among uropathogens causing cystitis. Methods: The study was carried out between 2017-2018. A total of 2060 UTI suspects from outpatient department (OPDs) and inpatient department (IPDs) were screened. Out of 2060 screened patients 1658 were IPD patients and 402 were OPD patients. Patient’s midstream urine samples were collected aseptically and processed according to standard protocols. The frequency of extended-spectrum-beta lactamases (ESBLs) producer and carbapenem resistance were estimated respectively. Cultures with significant growth of uropathogens were identified and minimum inhibitory concentration (MIC) to fosfomycin was determined by agar dilution (AD) and by E-test methods. Results: 184 out of 2060 (8.9%) urine samples showed significant growth of uropathogens. Uropathogenic Escherichia coli (UPEC) (64%,118/184) was found to be the mostly isolated uropathogen. Among these Gram-negative uropathogens, 80% were ESBLs producers, 43.2% were carbapenem-resistant and 78% isolates were found to be MDR. The fosfomycin susceptibility for UPEC was 95% by AD method. Conclusions: This study suggests that Fosfomycin is reasonably effective and can be used in the treatment of MDR uropathogens along with uncomplicated UTIs.